differences were found for section ratio between PRGFtreated tendons and the placebo group for any of the time periods evaluated. At 2 weeks, PRGF-treated tendons had higher tension ratio compared with placebo group tendons (p = 0.0143). Both PRGF and placebo treatments significantly improved the force (p < 0.001 and p = 0.0095, respectively) and tension (p = 0.009 and p = 0.0039, respectively) ratios at 8 weeks compared with 2 weeks. Conclusion The application of PRGF increases Achilles tendon repair strength at 8 weeks compared with the use of placebo. The use of PRGF does not modify section and tension ratios compared with placebo at 8 weeks. The tension ratio progressively increases between 2 and 8 weeks compared with the placebo.
Introduction
Tendon injuries are very common, and the Achilles is one of the most commonly involved [2, 16] . The Achilles tendon supports loads 10 times higher than the body weight [25] . Due to its viscoelastic properties, the tendon has high resistance to elongation before the breaking point [20, 31] . However, when the tendon ruptures, the healing potential is low because of poor vascularization and low cell metabolic rate [13] . Therefore, an attempt to improve tendon healing and biomechanical properties seems timely.
Platelets are known to have a critical role in the initiation and maintenance of the repair and regeneration of tissues [3, 10] . A large number of growth factors and other biologically active proteins that play important roles in the process of tendon repair are found inside the alpha granules [3] . The use of both platelet-rich plasma (PRP) and plasma rich in growth factors (PRGF) has demonstrated to improve the healing of Achilles tendon injuries [14, 17, 23, 30, 32] . PRGF is a specific type of PRP poor in leucocytes. The main difference with PRP is the method used for obtaining PRGF and its final composition [6, 14] .
Histological studies have demonstrated that the use of PRGF on the healing Achilles tendon produced better nuclei orientation of the tendon fibroblasts, better organization of the collagen fibres, lower inflammatory cell infiltration, faster vascular regression and lower density of fibroblasts compared with a placebo group [14] . This study employed an animal model (i.e. sheep) with tendon size similar to the human specie. From a biomechanical standpoint, previous studies related to Achilles tendon repair have used PRP preparation in a rat or rabbit model [7, 17, 18, 32] . However, there are obvious differences in tendon size (length and thickness) between rats/ rabbits and humans. Therefore, the novel aspect of this study would be the investigation of the effects of PRGF on the biomechanical properties of Achilles tendon repair in an animal model with tendon size characteristics more comparable to humans. The clinical relevance of the present study would be to know whether PRGF can be potentially used in the clinical setting as a complementary therapy to surgical treatment in patients with Achilles tendon ruptures.
The purpose of this study was to assess whether the application of PRGF can improve the biomechanical properties of the Achilles tendon repair in sheep. It was hypothesized that the intra-tendinous injection of PRGF would improve force, section and tensile strength of the Achilles tendon repair compared with the injection of saline solution (placebo group).
Materials and methods

Procedures
The animal model was the young healthy adult Merino female sheep between 45 and 55 kg of body weight without orthopaedic disorders. A total of 30 animals (60 tendons) were randomly assigned into one of the six groups (five animals per group) depending on the type of treatment received (PRGF or placebo) and survival time (2, 4 and 8 weeks). The sample size was determined based on suitability for the preceding histological study by Fernán-dez-Sarmiento et al. [14] . After sectioning and suturing the Achilles tendon, half of the animals were treated with intra-tendinous injection of PRGF and half with intra-tendinous injection of saline solution. Animals were killed at weeks 2, 4 or 8. For each study period, the tendon force, section and tension were measured in the operated and contralateral healthy Achilles tendons. These biomechanical variables were then compared among all groups. The sheep model employed in this study is considered suitable to study Achilles tendon repairs because of easy surgical access, similar length and thickness compared with human Achilles tendons, and adequacy for biomechanical testing [4, 22] .
Treatment groups
The animals were placed under general anaesthesia and had their right hind limbs aseptically prepared for surgery. An approach was made to the Achilles tendon by accessing its lateral face at approximately 2 cm from the calcaneal tuberosity and was extended 8 cm approximately. The surrounding fascia was released, and the paratenon was cut longitudinally, clearly exposing the Achilles tendon. Then, with the help of a ruler, a mark was made 5 cm from the insertion of the tendon into the calcaneus tuberosity. Before performing the tenotomy, a pre-suture was placed using a triple pulley pattern. This triple pulley pattern suture was carried out in a standardized manner using a non-absorbable monofilament (polypropylene) (Premilene USP 1, B Braun Aesculap, Melsungen, Germany). The tenotomy was then performed 5 cm proximal to the Achilles tendon insertion at the level marked previously. The suture was carefully tied and knotted, ensuring that tendon edges were well positioned. Subsequently, an intra-operative, intra-tendinous PRGF or saline solution injection was applied using a 23G-gauge needle. A total of 1 ml was administered in each tendon edge. Finally, the wounds were closed using a simple discontinuous pattern. An external trans-articular fixator was placed connecting the tibia and the tarsus setting the ankle joint to be locked at an angle of 140° to ensure enough immobilization and to not compromise the tendon repair.
PRGF Endoret ® system [Biotechnology Institute (BTI), Vitoria, Spain] was used for obtaining PRGF. Four 5-ml blood tubes containing 0.5 mL of 3.8 % sodium citrate as anticoagulant were extracted. The blood was then centrifuged at 630G for a period of 8 min. After centrifugation, three different blood fractions were separated according to density: a plasma fraction, an intermediate line corresponding to leucocyte and an erythrocyte sediment. A total of 0.5 ml of PRGF from the plasma portion that lies just above the leucocytic line was used. To obtain this portion, a process of pipetting fractionated in laminar flow was used and a total of 2 ml of PRGF (0.5 ml from each of the four tubes) was obtained. PRGF were then loaded into a syringe, and prior to intra-tendinous application, the platelets were activated by addition of calcium chloride [5, 6] .
In addition to the first intra-operative injection, all sheep received two (the animals killed at 2 weeks) or three (the rest of the animals) ultrasound-guided injections of PRGF or saline solution during the post-operative period on a weekly basis. Weekly physical and orthopaedic examinations were performed and the degree of lameness evaluated.
Measurement methods
Once the animals were killed at weeks 2, 4 or 8, the external fixators were removed and both operated and healthy tendons (control) were extracted including the bone and all proximal muscular tissue. All tendons were placed in plastic bags with an individual identification number, and each pair of tendons from the same animal was placed in a re-sealable numbered bag. The samples were frozen at −20 °C and transported in an insulated container with dry ice (solid CO 2 ) to the Institute of Biomechanics of Valencia (IBV), where they were stored at −80 °C until biomechanical testing was to be carried out.
A total of 60 tendons (20 for each study period) were obtained. Additionally, four more tendons from surplus sheep from other studies were used for calibration and preliminary biomechanical testing. These four extra tendons were used to identify limitations in the biomechanical measurement methods. The two limitations observed were the inclusion of bone structures and the tissue slippage. A decision was taken to remove the calcaneus from all samples. To avoid slippage, the samples were fixed to the testing machine using low profile knurled-surface clamps with deposits for the freezing fluid so that the whole tissueclamp system could be frozen ( Fig. 1 ) [8] .
Samples were thawed during the day before the test and placed in a refrigerator at +5 °C. The calcaneus, excess muscle and suture used during the healing phase were removed. Each clamp was placed at 1′5 cm from the tendon repair area (3 cm of space in between clamps). The samples were placed between the clamps wrapped with a surgical gauze and cotton cloth to prevent tissue contact with the metal. Then, the clamps were fixed by uneven tightening of the screws and placed in the universal testing machine. System freezing began using laboratory-grade acetone poured into the clamp deposits and adding solid CO 2 to gradually freeze the soft tissue-clamp system avoiding freezing of the tested area (Fig. 1a) . The freezing process was monitored by a laser thermometer to prevent freezing of the tested area. After obtaining the freezing of the tissue-clamp system, testing was initiated at a tensile speed of 0.4 mm/s (Fig. 1b) .
The biomechanical outcomes measured in the present study were the ratio of force, section and tension between the operated and healthy tendons (expressed in %). The force ratio was obtained by dividing the maximum force in Newtons (N) of the operated tendon by the maximum force of the healthy tendon and multiplied by 100. The section ratio was obtained by dividing the cross-sectional area in mm 2 of the operated tendon by the cross-sectional area of the healthy tendon and multiplied by 100. The tension ratio was obtained by dividing the maximum tension in megapascals (MPa) of the operated tendon by the maximum tension of the healthy tendon and multiplied by 100. The tension was calculated by dividing the maximum breaking force recorded during the test by the section of the tested tendon. This study was approved by the Bioethics Committee of the Junta de Andalucía (Consejería de Agricultura y Pesca; approval number 19575).
Statistical analysis
Descriptive statistics were used to summarize values of force, section and tension ratios in all groups. Before the inter-group statistical comparison for the biomechanical outcomes, tests for normality (using the Shapiro-Wilk test) and homogeneity of variances (using the Levene test) were conducted. The Dixon Q test was also used to identify and reject outlier values. Given the type of study, data independence could be assumed. A 2 × 3 (treatment by time) analysis of variance (ANOVA) was conducted to compare biomechanical variables with normal distribution among all groups. For non-normal distribution variables, a KruskalWallis test was used for the inter-group comparison of biomechanical data. All statistical analyses were conducted with the software R (R Foundation for Statistical Computing, Vienna, Austria). The alpha level was set at 0.05. 
Results
No animals had to be discarded during the study. The mean (SD) duration of surgery was 51 min. The external fixation system remained intact throughout the post-operative period. Eight animals had clear discharge at the pins site without any sign of infection. The mechanical anchorage with clamps and the freezing system was adequate to assure accurate biomechanical testing. No tissue slippage or failures in the tissue-clamp system occurred. The 3 cm distance between clamps during the test proved to be wide enough to prevent freezing of the test area and permitted getting close enough to analyse the scar area. Table 1 summarizes the descriptive statistics for all biomechanical variables evaluated in the three groups. The comparison among all groups for force ratio is shown in Fig. 2 . Two values were considered outliers according to the Dixon Q test. At the 8-week period, the force ratio in the PRGF group was significantly higher compared with the placebo group (p = 0.007). PRGF and placebo treatments demonstrated significant increase in force ratio from 2 to 8 weeks (p < 0.001 in both cases).
The comparison of section ratio among all groups is shown in Fig. 3 . None of the values were considered outliers after applying the Dixon Q test. There were no significant differences in section ratio between the use of PRGF and placebo for any of the study periods. The use of PRGF produced a significant increase in section ratio at 4 weeks compared with 2 weeks, and a significant reduction in section ratio at 8 weeks compared with 4 weeks.
The tension parameter had two outlier values according to the Dixon Q test. These values were kept to avoid a too low number of samples available for the analysis. At 2 weeks, the PRGF tension ratio was significantly higher (p = 0.014) compared with the placebo group (Fig. 4) . The treatment with PRGF produced a significant increase in tension from weeks 2 to 8, but also from weeks 2 to 4 and 4 to 8 (Fig. 4) . PRGF and placebo treatments demonstrated higher tension ratio values at 8 weeks compared with 2 weeks (p = 0.009 and p = 0.039, respectively) (Fig. 4) .
Discussion
The principal finding of this study was the between-treatment differences for force ratio after Achilles tendon repair. The PRGF-treated tendons were biomechanically stronger compared with placebo-treated tendons. Section and tension ratios were essentially similar between treatment groups, except a higher tension ratio in the PRGF compared with the placebo group at 2 weeks.
The use of sheep is an adequate model for basic science investigations of Achilles tendon injuries. The dimensions of the Achilles tendon of the sheep provide enough tissue to perform biomechanical testing, and it is similar in size (length and thickness) to the human Achilles tendon [22, 26] . In addition, the weight of the sheep is closer to humans, as compared to the use of smaller animals previously employed (i.e. rats). The methods employed in this study in terms of tissue fixation, freezing and testing velocity share some similarities but also differences from previous studies. The present study used external clamps for tissue fixation into the testing machine. Similar methods have been successfully employed in several other orthopaedic experiments [12, 14, 28] . Previous studies with rat model have kept the tendon attachment to bone [17, 32] . Given that the mechanically weakest point in preliminary testing was the tendon-to-bone attachment, a decision was made to remove the calcaneus. The freezing method employed in the present study differs from previous investigations using liquid nitrogen into the tanks of the clamp [8] , or immersing clamp in liquid nitrogen [11, 17, 23, 32] . The use of acetone and solid CO 2 was adequate to ensure sufficient tissue grip and avoid the freezing of the tested area. Liquid nitrogen provides rapid freezing which may increase the risk of soft tissue freezing between the clamps. The testing velocity was based on previous studies [8] . Mechanical properties of tendons are affected by the testing velocity due to its viscoelastic characteristics [31] . Too high velocity testing was avoided because water is not removed from the tissue, increasing its rigidity [27] .
Biomechanical studies usually involve force measurements through load cells of universal testing machines [15, 21] . The decision to report the outcomes as ratio (in %) between operated and healthy tendons decreases the effect that variability between animals may have on the results [19] . The inclusion of the tension variable (force/section) is what sets the current study apart from other published studies, but also greatly complicates the analysis and interpretation of results. This variable is used in studies with all kinds of materials in which the section is maintained during the test [1, 24] . However, tendons change their section as the tissue is stretched. Therefore, changes in section without changes in force may elicit different tension values. At the beginning of the test, tension is low as little force is applied over a large section, but as the tendon is stretched the section is reduced and the tension increases. Tension should be measured just before the tendon ruptures, giving the maximum tension value for a given section. The tension parameter was included in the present study because it provides more information on the quality of the scar tissue that forms in the healing tendon.
The results of the present study show that tendons treated with PRGF are stronger at 8 weeks compared with placebotreated tendons. This provides a biomechanical basis for the results obtained by Fernández-Sarmiento et al. [14] , who observed a more elongated silhouette, more type-I collagen and better core orientation of tendon fibroblasts with PRGF compared with placebo after 8 weeks (better histological characteristics). In addition, the results observed in the present study for force ratio also support the results observed in other studies [4, 26, 31] . It was found that the use of PRP in Achilles tendon produced a faster maturity of the scar tissue in rats [17] . In fact, rats treated with PRP or placebo had increased tendon resistance in the first weeks and later stabilized regardless of treatment [17] , which corresponds to the findings of the present investigation. Interestingly, Kaux et al. [17] also observed significantly higher force for PRP-treated animals compared with placebo at 8 weeks. In the rat model, it has been concluded that the application of PRP improves the strength of the tendons until 42 days [29] . However, caution must be taken when comparing the results of the present study with previous studies, as differences in the animal model or PRGF preparation may explain different results [6, 14, 29] .
Overall, section ratios of the samples showed no significant differences among groups. However, section ratio in PRGF-treated tendons at 4 weeks was significantly higher compared with 2 and 8 weeks. It has been demonstrated that sections evidently change in the early days in PRPtreated rats, and evened out after a longer time in the placebo-matched group [17] . This result means that the sizes of healing scars in the tenotomy areas do not vary significantly between weeks 2 and 8 for the placebo group. Our findings for section ratio changes were similar to those observed by Kaux et al. [17] in their rat model. With PRGF, repair scars significantly increase from weeks 2 to 4 and then significantly decrease in size from weeks 4 to 8, whereas the placebo treatment shows no significant section changes throughout the study period. Time-related changes in section ratio in PRGF-treated tendons may be explained by an earlier initiation of the inflammatory and reparative processes with lower inflammatory infiltration at weeks 4 and 8 leading to early thickening [14] .
The PRGF-treated tendons demonstrated significantly higher tension ratio at week 2 compared with placebotreated tendons. Therefore, it may be interpreted that the scar tissue of tendons treated with PRGF withstands more force per unit area. This may indicate a higher quality of the scar tissue in tendons treated with PRGF compared with those treated with placebo. This would coincide with the results obtained by Fernández-Sarmiento et al. [14] , where tendons treated with PRGF proved to have an earlier period of maturity and matured faster than those treated with saline solution, despite histological studies at week 2. Although histological analysis was not carried out in the present investigation, it is reasonable to expect that better collagen fibres and structure would confer an increased resistance of the scar tissue [14] . It has also been shown that PRGF-treated supraspinatus tendons in rats produce an early improved resistance of the tendon and a greater infiltration of fibroblast and greater alignment of fibroblast in the longitudinal axis of the tendon [9] . The placebotreated tendons exhibited a significant increase in tension ratio from weeks 2 to 4, but not from 4 to 8 weeks, whereas the PRGF-treated tendons significantly increased tension between all time periods. This can be interpreted as an improvement in the tissue quality of tendons treated with PRGF, causing the tension ratio to gradually progress from 2 to 8 weeks. This could correspond with previous histological studies on the effects of PRGF using the same animal model [14] .
This study has some limitations. First, the sample size was small. This may explain the absence of significant between-treatment differences at some time periods, especially in those where a trend towards significance was observed (force ratio at 2 weeks). However, a small number of sheep per group have not affected the comparisons where significant differences were observed. Therefore, some of the main conclusions of the study were not affected by a limited sample size. Second, the presence of abnormal high or low values (highly dispersed values) may explain the absence of significant differences in studies with small sample size. Although the Dixon Q test was employed to rule out outliers, other values not classified as outliers but obviously high or low were not discarded as to not further decrease the sample size. Third, tension was a calculated rather than a measured parameter. Therefore, abnormal force and section values affected the final tension ratio values. However, tension was relevant to calculate because it provides further information on how a certain section resists forces, which may be related to the quality of the scar tissue. On the other hand, this study provides valuable information on the biomechanical effects of PRGF on Achilles tendon repair in an in vivo model. In addition, this study uses an animal model closer to humans and evaluates both early (2 weeks) and late (8 weeks) biomechanical effects. The clinical relevance of the present study is that PRGF may potentially be used in the clinical setting as a complementary therapy to surgical treatment in patients with Achilles tendon ruptures in order to improve the strength of the repair.
Conclusion
The application of PRGF increases Achilles tendon repair strength at 8 weeks compared with the use of placebo. The use of PRGF does not modify section and tension ratios compared with placebo at 8 weeks. The tension ratio progressively increases between 2 and 8 weeks compared with the placebo.
